NASDAQ:CTIC
Delisted
CTI BioPharma Stock News
$9.09
+0 (+0%)
At Close: Sep 22, 2023
CTI BioPharma skyrockets on acquisition by Sobi
11:13am, Wednesday, 10'th May 2023
CTI BioPharma shares added almost 85% on the news that the company would be acquired by Stockholm-based hematology and immunology leader Swedish Orphan Biovitrum AB (Sobi). Seattle-based CTI is a biop
Why Shares of CTI BioPharma Are Soaring Wednesday
10:51am, Wednesday, 10'th May 2023
CTI BioPharma has one FDA-approved therapy, Vonjo, to treat a rare form of bone marrow cancer. The company is being bought at a 89% premium from its closing price on Tuesday.
U.S. stock futures climb as inflation continues to cool
09:26am, Wednesday, 10'th May 2023
U.S. stock index futures climbed on Wednesday after data showed U.S. consumer price inflation cooled to lowest annual rate in two years in April, though the core inflation, which excludes food and ene
Why Is CTI BioPharma (CTIC) Stock Up 85% Today?
08:25am, Wednesday, 10'th May 2023
CTI BioPharma (NASDAQ: CTIC ) stock is taking off on Wednesday after the company announced a major acquisition deal with Sobi. This deal has Sobi agreeing to acquire CTI BioPharma for $1.7 billion.
CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.
07:05am, Wednesday, 10'th May 2023
Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio.
CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings
05:39am, Wednesday, 10'th May 2023
CTI BioPharma Corp. CTIC stock soared 83% in premarket trading after Swedish Orphan Biovitrum AB SE:SOBI said it had entered into an agreement to acquire the biotech in a deal valued at $1.7 billion.
Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion
02:26am, Wednesday, 10'th May 2023
Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a deal valued at $1.7 billion. The Stockholm-based dr
CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023
04:46pm, Monday, 01'st May 2023
SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-
VONJO Keeps CTI BioPharma A Buy
07:46am, Friday, 21'st Apr 2023
VONJO Keeps CTI BioPharma A Buy.
CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023
04:30pm, Wednesday, 12'th Apr 2023
SEATTLE, Wash. , April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies
These Are the Top 10 Holdings of David Kim
10:55pm, Monday, 06'th Mar 2023
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20
CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates
09:02am, Monday, 06'th Mar 2023
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -55.56% and 15.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma to Present at the 43rd Annual Cowen Health Care Conference
04:20pm, Wednesday, 01'st Mar 2023
SEATTLE , March 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for bloo
CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023
07:03am, Thursday, 23'rd Feb 2023
SEATTLE , Feb. 23, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blo
CTI BioPharma: Limited Cash Runway, But Better Than Expected Commercial Launch
07:54am, Friday, 20'th Jan 2023
CTI BioPharma has reported a better-than-expected Q3 print of 18.5M, which is a 40% growth QoQ, and we expect this growth to continue reaching close to USD60M in FY2022. CTIC's Vonjo (Pacritinib) is a